Atul Pande

Atul C.
Pande currently works at Verity BioConsulting LLC, as President & Chief Executive Officer from 2014, Roivant Sciences, Inc., as Director, Immunovant Sciences Ltd., as Director from 2019, Immunovant, Inc., as Independent Director from 2019, and Pangea Botanica Ltd., as Non-Executive Director from 2022.
Dr. Pande also formerly worked at Nxera Pharma UK Ltd., as Director, Parke-Davis Pharmaceutical Research, Inc., as Senior Director, Sio Gene Therapies, Inc., as Lead Independent Director from 2018 to 2023, Immunovant, Inc., as Director, Karuna Therapeutics, Inc., as Independent Director from 2019 to 2024, Autifony Therapeutics Ltd., as Non-Executive Director from 2013 to 2023, Perception Neuroscience, Inc., as Non-Executive Director from 2019 to 2023, Eli Lilly & Co., as Vice President, Pfizer Inc., as Vice President-Neurosciences, CeNeRx BioPharma, Inc., as Chief Medical Officer, Tal Medical, Inc., as Chief Medical Officer & Executive Vice President from 2014 to 2017, GSK Plc, as Senior Vice President from 2007 to 2014, Lilly Research Laboratories, as Principal, the University of Michigan Medical School, as Assistant Professor, and PureTech Health Plc, as Chief Medical Officer from 2017 to 2018.
Dr. Pande received his undergraduate degree and doctorate degree from the University of Lucknow.